Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-25-10
Credit Expiration Date: November-04-11

Faculty

Robert Lee Page II, PharmD, MSPH, FCCP, FAHA, BCPS
Associate Professor
Department of Clinical Pharmacy
Associate Professor
Department of Physical Medicine/Rehabilitation
University of Colorado School of Pharmacy
Aurora, CO


Steven A. Rothman, MD, FACC
Clinical Associate Professor
Lankenau Institute of Medical Research
Campus Chief, Cardiovascular Diseases
Lankenau Hospital, MLH Heart Center
Wynnewood, PA

Credit Hours

1

Medium

Online Presentation

Program Description

THIS ACTIVITY WAS ORIGINALLY PRESENTED AS AN AUDIOCONFERENCE SERIES BEGINNING AUGUST 25, 2010. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE RELEASE.

Approximately 2.2 million people in the United States have been diagnosed with atrial fibrillation (AF), the most common cardiac arrhythmia, and the risk for stroke in these patients is substantial. In older adults, AF leads to 25% of all strokes. Guidelines for the management of patients with AF emphasize risk assessment to determine which patients are likely to benefit from anticoagulant therapy. Long-term anticoagulation is recommended for all AF patients who have risk factors for thromboembolism. Many older adults with AF receive inadequate risk assessment, however, and anticoagulation therapy is often not initiated or optimized.

Senior care clinicians play an important role in ensuring that older adults with AF benefit from optimal anticoagulant therapy to prevent stroke. This activity seeks to enhance clinicians' abilities to determine when the risk for stroke in elderly patients with AF exceeds the risk for anticoagulation-associated bleeding, to identify optimal anticoagulant agents, and to maintain the ideal therapeutic range for therapy for each patient. Emerging anticoagulants and their unique characteristics will also be discussed. Because of the serious and immediate consequences of strokes, effective preventive treatment is of the utmost importance in reducing disability and improving survival in elderly patients with AF.

Target Audience

This knowledge-based educational activity is designed to meet the needs of healthcare professionals in eldercare settings, including consultant and VA pharmacists, medical directors, gerontological nurse practitioners, long-term care nurses, and other pharmacists, physicians, physician assistants, nurse practitioners, and nurses involved in the care of older patients with atrial fibrillation.

Learning Objectives

Upon completion of this knowledge-based educational activity, the participant should be able to:

  1. Assess when the risk for stroke in elderly patients with atrial fibrillation exceeds the risk for anticoagulation-associated bleeding.
  2. Identify optimal anticoagulant strategies for individual patients with atrial fibrillation based on a comprehensive risk/benefit assessment.
  3. Describe how to coordinate with the clinical care team to ensure that elderly patients with atrial fibrillation achieve and maintain a therapeutic range with anticoagulation therapy.
  4. Summarize the potential role of emerging anticoagulant agents for the prevention of stroke in patients with atrial fibrillation.

Disclosures

It is the policy of ASCP, AKH Inc, and NADONA/LTC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activities or with the commercial supporter of these continuing education activities. Identified conflict of interest is resolved by the providers prior to accreditation of the activities. ASCP, AKH Inc, and NADONA/LTC planners and reviewers have no relevant financial relationships to disclose.

Dr. Page discloses that he has served on the speakers' bureau for AstraZeneca and Dr. Rothman discloses that he has served as a consultant for AstraZeneca and on the speakers' bureau for sanofi-aventis.

Credit Statements

Pharmacy Continuing Education: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity (UAN: 203-999-10-069-H01-P) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU).

Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number 030803. AKH Inc. designates this educational activity for 1 contact hour.

Nursing Continuing Education: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1088. This activity provides 1 contact hour by NADONA/LTC.

Participants must successfully complete the post test (70% or higher) and submit an evaluation to receive credit. A statement of credit will be available immediately if the post-test and evaluation are completed online, or mailed within 4-6 weeks if they are submitted by mail. There is no fee to participate in this activity.

Commercial Support Statements

Supported through an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions

  1. Minimum System Requirements:
    • Pentium III, 600 MHz or Equivalent Processor
    • 512 MB of RAM
    • Windows XP, Vista, or 7
    • Mac OS X
    • 800x600 Monitor Resolution
    • 16-bit Color
    • 16 bit Sound Card with Speakers
  2. Please turn off all pop-up blockers to assure access to the educational activity.
  3. Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  4. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
  5. After the activity has finished, click on the "Post-test" button.
  6. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.

Certificate Fee

$0.00

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS